BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29328939)

  • 1. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy.
    Brun JL; Rajaonarison J; Froeliger A; Monseau-Thiburce AC; Randriamboavonjy R; Vogler A
    Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():13-18. PubMed ID: 29328939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs.
    Badiani B; Chiumente M; Messori A
    Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():84-88. PubMed ID: 29408752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
    Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
    Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulipristal acetate versus placebo for fibroid treatment before surgery.
    Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
    N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
    Woodhead N; Pounds R; Irani S; Pradhan P
    J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results.
    Fernandez H; Schmidt T; Powell M; Costa AP; Arriagada P; Thaler C
    Eur J Obstet Gynecol Reprod Biol; 2017 Jan; 208():91-96. PubMed ID: 27898340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids.
    Ciebiera M; Włodarczyk M; Wrzosek M; Słabuszewska-Jóźwiak A; Nowicka G; Jakiel G
    Fertil Steril; 2018 Mar; 109(3):501-507.e2. PubMed ID: 29525690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review.
    Donnez J; Courtoy GE; Donnez O; Dolmans MM
    Reprod Biomed Online; 2018 Aug; 37(2):216-223. PubMed ID: 29706284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
    Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
    Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
    Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
    Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term medical management of uterine fibroids with ulipristal acetate.
    Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
    Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
    Murji A; Crosier R; Chow T; Ye XY; Shirreff L
    Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of ulipristal acetate in female patients with uterine fibroids.
    Grzechocinska B; Gadomska H; Zygula A; Wielgos M
    Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
    Szamatowicz M; Kotarski J
    Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
    Laberge PY; Murji A; Vilos GA; Allaire C; Leyland N; Singh SS
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1521-1524. PubMed ID: 31548041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
    Talaulikar VS; Manyonda I
    Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study.
    Frijlingh M; De Milliano I; Hehenkamp WJK; Huirne JAF
    Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():186-192. PubMed ID: 31679806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
    Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
    Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
    Pérez-López FR
    Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
    Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
    Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.